Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:446284
Structure:
Synonyms:
(5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid
(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
(all-cis)-5,8,11,14,17-Eicosapentaenoic acid
(all-Z)-5,8,11,14,17-Eicosapentaenoic acid
(all-Z)-delta5,8,11,14,17-Eicosapentaenoic acid
(Z,Z,Z,Z,Z)-5,8,11,14,17-eicosapentaenoic acid
10417-94-4
1553-41-9
1553-41-9 (CIS/TRANS UNDEFINED)
25377-48-4
3gwx
44864_FLUKA
5,8,11,14,17-Eicosapentaenoic acid
5,8,11,14,17-Eicosapentaenoic acid (6CI)
5,8,11,14,17-EICOSAPENTAENOIC ACID (All CIS)
5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)-
5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)- (9CI)
5,8,11,14,17-Eicosapentaenoic acid, (all-Z)-
5,8,11,14,17-Eicosapentaenoic acid, (all-Z)- (8CI)
5,8,11,14,17-Icosapentaenoic acid
5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid
7F8BF016-B146-4F72-A52E-B9298BA3A9AB
AC1L9JFR
AIDS-082784
AIDS082784
all cis-5,8,11,14,17-Eicosapentaenoic Acid
all cis-5,8,11,14,17-Icosapentaenoic Acid
all-cis-icosa-5,8,11,14,17-pentaenoic acid
BML3-B01
BRD-K47192521-001-02-1
BSPBio_001328
C06428
C20:5 omega-3
CCRIS 3279
CHEBI:28364
CHEMBL460026
cis, cis, cis, cis, cis-eicosa-5,8,11,14,17-pentaenoic acid
cis-5,8,11,14,17-Eicosapentaenoic acid
cis-5,8,11,14,17-EPA
cis-Delta(5,8,11,14,17)-eicosapentaenoic acid
D08061
DB00159
E0441
E2011_SIGMA
E7006_SIGMA
Eicosapentaenoic acid
EICOSAPENTAENOIC ACID (20:5 n-3)
Eicosapentaenoic acid, 5,8,11,14,17-(Z,Z,Z,Z,Z)-
EPA
HMS1361C10
HMS1791C10
HMS1989C10
Icosapent
Icosapent [INN]
Icosapentaenoic acid
Icosapento
Icosapento [INN-Spanish]
Icosapentum
Icosapentum [INN-Latin]
IDI1_033798
L001256
LMFA01030759
NCGC00161344-01
NCGC00161344-02
NCGC00161344-03
NCGC00161344-04
Timnodonic acid
Timnodonic acid;

Target

show target details
Uniprot ID:CP1A2_HUMAN
Synonyms:
CYPIA2
Cytochrome P450 1A2
P(3)450
P450 4
P450-P3
EC-Numbers:1.14.14.1
Organism:Homo sapiens
Human
PDB IDs:2HI4
Structure:
2HI4

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

16978661
The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.. Hsien-Tsung Yao; Yi-Wei Chang; Shih-Jung Lan; Chiung-Tong Chen; John T A Hsu; Teng-Kuang Yeh (2006) Life sciences display abstract
The inhibitory effect of saturated fatty acids (SFAs): palmitic acid (PA), stearic acid (SA) and polyunsaturated fatty acids (PUFAs): linoleic acid (LA), linolenic acid (LN), arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on six human drug-metabolizing enzymes (CYP1A2, 2C9, 2C19, 2D6, 2E1 and 3A4) was studied. Supersomes from baculovirus-expressing single isoforms were used as the enzyme source. Phenacetin O-deethylation (CYP1A2), diclofenac 4-hydroxylation (CYP2C9), mephenytoin 4-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), chlorzoxazone 6-hydroxylation (CYP2E1) and midazolam 1-hydroxylation (CYP3A4) were used as the probes. Results show that all the five examined PUFAs competitively inhibited CYP2C9- and CYP2C19-catalyzed metabolic reactions, with Ki values ranging from 1.7 to 4.7 microM and 2.3 to 7.4 microM, respectively. Among these, AA, EPA and DHA tended to have greater inhibitory potencies (lower IC(50) and Ki values) than LA and LN. In addition, these five PUFAs also competitively inhibited the metabolic reactions catalyzed by CYP1A2, 2E1 and 3A4 to a lesser extent (Ki values>10 microM). On the other hand, palmitic and stearic acids, the saturated fatty acids, had no inhibitory effect on the activities of six human CYP isozymes at concentrations up to 200 microM. Incubation of PUFAs with CYP2C9 or CYP2C19 in the presence of NADPH resulted in the decrease of PUFA concentrations in the incubation mixtures. These results indicate that the PUFAs are potent inhibitors as well as the substrates of CYP2C9 and CYP2C19.